3 Healthcare Stock Stories For Weekend Investment Wellness

Merck & Co. (NYSE:MRK): Closing price $45.67

On Friday, Marck reported that the FDA has approved Liptruzet (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein  cholesterol in patients suffering from primary or mixed hyperlipidemia as adjunctive therapy to diet, when diet alone is insufficent. The drug contains ezetimibe, an efficacious LDL cholesterol lowering therapy, and atorvastatin, presently one of the most widely prescribed statins in the United States. Once-daily Liptruzet treats two sources of cholesterol by inhibiting both the absorption of cholesterol in the digestive tract through ezetimibe and the output of cholesterol in the liver through atorvastatin.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MRK

 Chemed Corporation (NYSE:CHE): Closing price $68.00

Justice Department is suing Chemed and its hospice subsidiaries, which include the largest domestic for-profit hospice chain, claiming false billings for Medicare hospice services. The government elaborated that its complaint accuses Chemed and its leading hospice subsidiary, Vitas Hospice Services, of involvement in the submission of false claims for crisis care services that turned out unnecessary, and were never actually provided or did not meet Medicare requirements. The firms used aggressive marketing tactics and pressured staff to increase the amount of crisis care claims submitted to Medicare, whether they were valid or not, said the Justice Department.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CHE

Genetic Technologies Limited (NASDAQ: GENE): Closing price $2.65

The firm announced that it has reached a credentials agreement with Three Rivers Provider Network of Chula Vista, California. The latter claims to be the number-one supplemental PPO Network Foundation in the United States, providing healthcare benefits to over 10 million members, at more than 1 million locations across the country. The arrangement with Three Rivers is the fifth such agreement made between Genetic and similar American Preferred Provider Organisations, and increases the total number of covered lives, for which its BREVAGen” test could be adjudicated as “in-network,” to more than 23 million.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GENE

Investing Insights: Can CVS Compete With Walgreen in This Different Arena?